^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    FGFR2 amplification

    i
    Entrez ID:
    2263
    Related biomarkers:
    Expression
    Mutation
    Fusion
    Others
    Apply
    Futibatinib in Patients With Specific FGFR Aberrations (TAS-120-202) (NCT04189445)
    Phase 2
    Taiho Oncology, Inc.
    Active, not recruiting
    Last update posted :
    02/05/2025
    Initiation :
    08/24/2020
    Primary completion :
    11/11/2024
    Completion :
    03/31/2025
    FGFR2
    |
    FGFR2 amplification • FGFR1 rearrangement
    |
    Lytgobi (futibatinib)
    A Study of TAS-120 in Patients With Metastatic Breast Cancer (FOENIX-MBC2 TAS-120-201) (NCT04024436)
    Phase 2
    Taiho Oncology, Inc.
    Active, not recruiting
    Last update posted :
    05/29/2024
    Initiation :
    08/30/2019
    Primary completion :
    05/31/2023
    Completion :
    07/05/2024
    HER-2 • PD-L1 • FGFR2
    |
    HER-2 amplification • HER-2 negative • FGFR1 amplification • FGFR2 amplification
    |
    fulvestrant • Lytgobi (futibatinib)
    A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer (FIGHT) (NCT03694522)
    Phase 2
    Five Prime Therapeutics, Inc.
    Completed
    Last update posted :
    02/28/2024
    Initiation :
    09/14/2018
    Primary completion :
    09/23/2020
    Completion :
    05/13/2022
    FGFR2
    |
    FGFR2 amplification • FGFR2 overexpression • FGFR2b overexpression
    |
    5-fluorouracil • oxaliplatin • leucovorin calcium • bemarituzumab (AMG 552)
    Nivolumab in Combination With Chemotherapy for FGFR2-positive Metastatic Gastric Cancer (NIVOFGFR2) (NCT05859477)
    Phase 2
    Kidney Cancer Research Bureau
    Recruiting
    Last update posted :
    01/01/2024
    Initiation :
    06/05/2022
    Primary completion :
    12/01/2023
    Completion :
    12/01/2024
    HER-2 • PD-L1 • FGFR2
    |
    HER-2 negative • FGFR2 amplification • FGFR2 overexpression • FGFR2 expression
    |
    Opdivo (nivolumab) • capecitabine • oxaliplatin
    A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors (NCT05627063)
    Phase 1
    Abbisko Therapeutics Co, Ltd
    Recruiting
    Last update posted :
    09/01/2023
    Initiation :
    06/26/2023
    Primary completion :
    03/15/2025
    Completion :
    06/30/2025
    FGFR2
    |
    FGFR2 mutation • FGFR2 fusion • FGFR2 amplification • FGFR3 mutation • FGFR3 S249C • FGFR2 rearrangement • FGFR3 Y373C • FGFR3 G370C • FGFR3 R248C
    |
    ABSK121
    Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations (NCT05019794)
    Phase 2a
    LianBio LLC
    Recruiting
    Last update posted :
    06/27/2022
    Initiation :
    05/13/2020
    Primary completion :
    12/30/2022
    Completion :
    12/30/2023
    FGFR2
    |
    FGFR2 amplification
    |
    Truseltiq (infigratinib)
    Study to Evaluate the Safety and Efficacy of Pazopanib, in Subject With Refractory Solid Tumors (NCT02691767)
    Phase N/A
    Samsung Medical Center
    Completed
    Last update posted :
    06/15/2022
    Initiation :
    05/01/2016
    Primary completion :
    01/16/2018
    Completion :
    02/13/2020
    FGFR2
    |
    FGFR2 amplification
    |
    pazopanib
    Single-arm Study to Evaluate the Safety and Efficacy of Pazopanib, in Subjects With FGFR2 Amplification, FGFR2 Mutation Refractory Solid Tumors (NCT02450136)
    Phase N/A
    Samsung Medical Center
    Completed
    Last update posted :
    06/15/2022
    Initiation :
    10/08/2015
    Primary completion :
    07/30/2017
    Completion :
    02/01/2018
    FGFR2
    |
    FGFR2 mutation • FGFR2 amplification
    |
    pazopanib
    HMPL-453 (FGFR Inhibitor) in Combination With Chemotherapy or Anti-PD-1 Antibody in Advanced Solid Tumors (NCT05173142)
    Phase 1/2
    Hutchison Medipharma Limited
    Recruiting
    Last update posted :
    03/08/2022
    Initiation :
    01/22/2022
    Primary completion :
    09/01/2024
    Completion :
    08/01/2025
    FGFR
    |
    PD-L1 expression • FGFR2 mutation • FGFR2 fusion • FGFR2 amplification • FGFR3 mutation • FGFR2 overexpression • FGFR2 expression • FGFR2 translocation
    |
    cisplatin • gemcitabine • docetaxel • Loqtorzi (toripalimab-tpzi) • Tevimbra (tislelizumab-jsgr) • fanregratinib (HMPL-453)
    Dovitinib for Gastric Cancer With FGFR2 Amplification: GASDOVI-1 (NCT01719549)
    Phase 2
    Asan Medical Center
    Completed
    Last update posted :
    01/07/2020
    Initiation :
    09/01/2012
    Primary completion :
    02/01/2016
    Completion :
    11/01/2016
    FGFR2
    |
    FGFR2 amplification
    |
    dovitinib (TKI258)
    A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies (NCT01004224)
    Phase 1
    Novartis Pharmaceuticals
    Completed
    Last update posted :
    10/04/2019
    Initiation :
    12/11/2009
    Primary completion :
    10/08/2018
    Completion :
    10/08/2018
    FGFR2 • FGFR3
    |
    FGFR1 amplification • FGFR2 mutation • FGFR2 amplification • FGFR3 mutation • FGFR3 amplification
    |
    Truseltiq (infigratinib)
    Study of Alofanib in Patients With Metastatic Gastric Cancer (RPT835GC1B) (NCT04071184)
    Phase 1b
    Russian Pharmaceutical Technologies
    Unknown status
    Last update posted :
    09/26/2019
    Initiation :
    05/26/2019
    Primary completion :
    10/01/2020
    Completion :
    12/01/2020
    FGFR2 • FRS2
    |
    FGFR2 fusion • FGFR2 amplification • FGFR2 overexpression • FGFR2 expression
    |
    alofanib (RPT835)